It is a long established fact that a reader of a page when looking at its layout.

    SmartKidney Dx*

    Tumor Analysis that helps determine the patient’s course of care. 

    • SmartKidney Dx is a biomarker-based, algorithm-driven direct tissue measurement that we believe predicts the presence or risk of metastases.
    • We believe it identifies patients who are candidates for additional therapy, due to undiagnosed micro-metastases by the current standard of care.
    • We believe this test will help accelerate the course of treatment by reducing risk of disease progression through early intervention.
    • SmartKidney Dx was developed in partnership and collaboration with Mayo Clinic and licensed with Mayo Ventures.
    *In development